A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Phase 2

Completed

• Conditions: Duchenne Muscular Dystrophy
• Interventions: Drug: Ataluren

• Registration Number: NCT03648827
• Lead Sponsor: PTC Therapeutics

Brief Summary

This study is designed to evaluate the ability of ataluren to increase dystrophin protein levels in muscle cells of participants with nmDMD. The study will evaluate the levels of dystrophin before and after 40 weeks of ataluren therapy using muscle biopsies and 2 validated assay methods, electrochemiluminescence (ECL) and immunohistochemistry.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-08-24
• Study First Submitted QC: 2018-08-24
• Study First Posted: 2018-08-27
• Study Start: 2018-12-21
• Primary Completion: 2020-10-23
• Study Completion: 2020-10-23
• Disposition First Submitted: 2021-01-26
• Disposition First Submitted QC: 2021-01-26
• Disposition First Posted: 2021-01-28
• Status Verified: 2022-02
• Results First Submitted: 2022-03-10
• Results First Submitted QC: 2022-03-10
• Last Update Submitted: 2022-03-10
• Results First Posted: 2022-04-05
• Last Update Posted: 2022-04-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 20

Inclusion Criteria

• Evidence of signed and dated informed consent/assent document(s) indicating that the participant (and/or his parent/legal guardian) has been informed of all pertinent aspects of the trial.
• Phenotypic evidence of duchenne muscular dystrophy (DMD) based on the onset of characteristic clinical symptoms or signs (for example, proximal muscle weakness, waddling gait, and Gowers' maneuver) and an elevated serum creatine kinase (CK). Medical documentation of phenotypic evidence of DMD needs to be provided upon request by the Sponsor's medical monitor.
• Documentation of the presence of a nonsense point mutation in the dystrophin gene as determined by gene sequencing. Review and approval of documentation by sponsor or designee is required prior to enrollment.
• Willing to undergo muscle biopsy.

Read More

Exclusion Criteria

• Ongoing intravenous (IV) aminoglycoside or IV vancomycin therapy.
• Known contra-indication to muscle biopsy (such as bleeding or clotting disorders).
• Prior or ongoing therapy with ataluren.
• Known hypersensitivity to any of the ingredients or excipients of the study drug (for example, refined polydextrose, polyethylene glycol 3350, poloxamer 407, mannitol 25C, crospovidone XL10, hydroxyethyl cellulose, colloidal silica, magnesium stearate).
• Exposure to another investigational drug within 2 months prior to start of study treatment, or ongoing participation in any interventional clinical trial.
• Requirement for daytime ventilator assistance or any use of invasive mechanical ventilation via tracheostomy. Evening non-invasive mechanical ventilation such as use of bilevel positive airway pressure (Bi-PAP) therapy is allowed.
• Elevated serum creatinine or cystatin C levels at screening.
• Prior or ongoing medical condition (for example, concomitant illness, psychiatric condition, behavioral disorder), medical history, physical findings or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the participant, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Ataluren	Ataluren	Participants will receive ataluren oral suspension 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 40 weeks.

Primary Outcome Measures

Name	Time	Method
Percent Change From Baseline in Dystrophin Level at Week 40, as Measured by ECL	Baseline, Week 40	The percent change in dystrophin level from baseline in ambulatory nonsense mutation duchenne muscular dystrophy (nmDMD) participants after treatment with ataluren for 40 weeks was analyzed using quantitative assay (ECL).The least square (LS) mean and 90% confidence interval (CI) were analyzed from a mixed-model repeated measures (MMRM) with factors of muscle locations and visits as fixed effects, and participants as a random effect.

Secondary Outcome Measures

Name	Time	Method
Percent Change From Baseline in Dystrophin Level at Week 40, as Determined by Immunohistochemistry (IHC) Membrane Stain Density	Baseline, Week 40	The percent change in dystrophin level from baseline in ambulatory nmDMD participants after 40 weeks of ataluren therapy was determined by IHC membrane stain density. The LS mean and 90% CI were analyzed from an MMRM with factors of muscle locations and visits as fixed effects, and participants as a random effect.

Trial Locations

Locations (9)

University of Minnesota; 🇺🇸 Minneapolis, Minnesota, United States

Texas Children's Hospital; 🇺🇸 Houston, Texas, United States

University of California, Los Angeles (UCLA); 🇺🇸 Los Angeles, California, United States

Children's Hospital of the King's Daughters; 🇺🇸 Norfolk, Virginia, United States

Phoenix Childrens Hospital; 🇺🇸 Phoenix, Arizona, United States

University of Texas Heath Science Center at San Antonio; 🇺🇸 San Antonio, Texas, United States

University of California (UC) Davis Medical Center; 🇺🇸 Sacramento, California, United States

Columbia University College of Physicians & Surgeons; 🇺🇸 New York, New York, United States

University of Kansas Medical Center; 🇺🇸 Kansas City, Kansas, United States